MARC record from Internet Archive

LEADER: 04664cam 22007694a 4500
001 ocm50494874
003 OCoLC
005 20200603225235.0
008 020812s2003 enkac b 001 0 eng
010 $a 2003276398
040 $aNLM$beng$cNLM$dDLC$dUKM$dHKP$dEYM$dVET$dBAKER$dNLGGC$dBTCTA$dCGC$dYDXCP$dIG#$dOCLCF$dOCLCO$dOCLCQ$dOCLCO$dAU@$dZQP
015 $aGBA2V4736$2bnb
016 7 $a101173080$2DNLM
019 $a52490715
020 $a0340764082
020 $a9780340764084
035 $a(OCoLC)50494874$z(OCoLC)52490715
042 $apcc
050 00 $aQP751$b.B445 2003
060 00 $a2003 E-416
060 10 $aWD 200.5.H8$bB565c 2003
082 04 $a616.123071$221
084 $a44.85$2bcl
100 1 $aBetteridge, John.
245 10 $aClinicians' guide to lipids and coronary heart disease /$cD.J. Betteridge and J.M. Morrell.
246 30 $aLipids and coronary heart disease
250 $a2nd ed.
260 $aLondon :$bArnold ;$aNew York :$bOxford University Press [distributor],$c2003.
300 $axvi, 368 pages :$billustrations, portraits ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aClinicians' guides
504 $aIncludes bibliographical references and index.
505 00 $aMachine derived contents note: Part One: Background -- 1. Lipid and lipoprotien metabolism -- the basics -- 2. Epidemiology -- Part Two: Screening and assessment -- 3. Diagnosis -- 4. Screening -- 5. Risk factors and their assessment -- Part Three: Intervention -- 6. Non-lipid risk factor modification -- 7. Diet -- 8. Lipid lowering drugs -- 9. Lipid lowering trials -- Part Four: Practical considerations and special areas -- 10. Meeting the challenge -- 11. Special areas -- 12. Economic aspects -- 13. Case studies.
520 $aThis fully updated revision of the well-received first edition provides a clear, comprehensive and up-to-date account of the role of lipid management in the prevention of coronary heart disease. Appropriate for the clinician managing lipid problems in either the primary or secondary care setting, the respected author team consider all aspects of screening, diagnosis, risk assessment and management. The science underlying lipid metabolism is put into context for the practising physician to facilitate understanding of the dyslipidaemias and the mechanisms of drug action. Risk factor modifications, including lifestyle change and cholesterol lowering by diet and medication, are discussed fully. Landmark clinical trials, and the messages that can be drawn from them, are highlighted throughout. The practical focus is maintained through the consideration of specific patient groups demonstrating particular clinical importance, management difficulties or areas of current controversy. With a balanced, readable.
520 8 $aStyle and clear explanatory illustrations, this second edition of Clinicians' Guide to Lipids and Coronary Heart Disease provides invaluable advice for primary care and specialist clinicians, whether in training or in practice, in the management of lipid disorders and the prevention of cardiovascular events.
650 0 $aLipids$xMetabolism.
650 0 $aCoronary heart disease$xEtiology.
650 0 $aCholesterol.
650 0 $aAnticholesteremic agents.
650 12 $aHyperlipidemias$xcomplications.
650 12 $aHyperlipidemias$xdiet therapy.
650 12 $aHyperlipidemias$xdrug therapy.
650 22 $aCoronary Disease$xprevention & control.
650 22 $aHypolipidemic Agents$xtherapeutic use.
650 22 $aLipid Metabolism.
650 7 $aAnticholesteremic agents.$2fast$0(OCoLC)fst00810458
650 7 $aCholesterol.$2fast$0(OCoLC)fst00858427
650 7 $aCoronary heart disease$xEtiology.$2fast$0(OCoLC)fst00879544
650 7 $aLipids$xMetabolism.$2fast$0(OCoLC)fst00999374
650 17 $aHart- en vaatziekten.$2gtt
650 17 $aLipiden.$2gtt
700 1 $aMorrell, J. M.
830 0 $aClinicians' guides.
856 41 $3Table of contents$uhttp://catdir.loc.gov/catdir/enhancements/fy0615/2003276398-t.html
856 42 $3Publisher description$uhttp://catdir.loc.gov/catdir/enhancements/fy0615/2003276398-d.html
938 $aBaker & Taylor$bBKTY$c49.95$d.00$i0340764082$n0004061023$sactive
938 $aBaker and Taylor$bBTCP$n2003276398
938 $aIngram$bINGR$n9780340764084
938 $aYBP Library Services$bYANK$n100324566
029 0 $aNLM$b101173080
029 1 $aAU@$b000024783090
029 1 $aNLGGC$b249738961
029 1 $aNZ1$b7975448
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 106 OTHER HOLDINGS